AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31343010 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (α-LA) supplementation (1200 mg/day, 600 mg per capsule, 2 capsules daily)
Number of subjects: 50
Study 31343010 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (2 capsules daily)
Number of subjects: 50
Study 28891772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy plus Hypnosis
Number of subjects: 100
Study 28891772 — intervention group
Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 100
Study 26934084 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon extract (6 g daily for 42 days)
Number of subjects: 43
Study 26934084 — intervention group
Group type: COMPARATOR
Intervention: Control group (mixture of carbohydrates: sucrose/glucose/fructose)
Number of subjects: 43
Study 26934084 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon extract (6 g daily for 42 days) in carriers of the T allele (MTHFR C677T)
Number of subjects: 43
Study 25475463 — intervention group
Group type: EXPERIMENTAL
Intervention: GA/TEE protocol
Number of subjects: 144
Study 25475463 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake TAVR protocol
Number of subjects: 144
Study 25475463 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid discharge group
Number of subjects: 144
Study 25475463 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge
Number of subjects: 144
Study 23082849 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR) with ProDisc-L
Number of subjects: 236
Study 23082849 — intervention group
Group type: COMPARATOR
Intervention: Circumferential Fusion
Number of subjects: 236
Study 19497646 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-based lipid emulsion (OO)
Number of subjects: 28
Study 19497646 — intervention group
Group type: COMPARATOR
Intervention: MCT/LCT lipid emulsion (M/L)
Number of subjects: 28
Study 17495205 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge Eating Disorder (BED) diagnosis
Number of subjects: 845
Study 17495205 — intervention group
Group type: EXPERIMENTAL
Intervention: Night Eating Syndrome (NES) diagnosis
Number of subjects: 845
Study 17495205 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with eating disorders
Number of subjects: 845
Study 14630619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 300 mg
Number of subjects: 178
Study 14630619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg
Number of subjects: 178
Study 14630619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 11781553 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg atropine intravenously (i.v.)
Number of subjects: 39
Study 11781553 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 39
Study 9767282 — intervention group
Group type: EXPERIMENTAL
Intervention: VML295
Number of subjects: 0
Study 9767282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7522392 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick, energy-dense porridge (4.09 kJ/g)
Number of subjects: 15
Study 7522392 — intervention group
Group type: COMPARATOR
Intervention: Traditional liquid, low-density porridge (2.15 kJ/g)
Number of subjects: 15
Study 7522392 — intervention group
Group type: COMPARATOR
Intervention: Amylase-treated thick energy-dense porridge
Number of subjects: 15
Study 2673340 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ethinyloestradiol gel
Number of subjects: 25
Study 2673340 — intervention group
Group type: COMPARATOR
Intervention: gel alone (control)
Number of subjects: 25
Study 29703576 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate characteristics (HRC) monitoring
Number of subjects: 3
Study 29703576 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 28342705 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol (5ml/kg)
Number of subjects: 40
Study 28342705 — intervention group
Group type: COMPARATOR
Intervention: 3% hypertonic saline (5.35ml/kg)
Number of subjects: 40
Study 26124205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with defibrillator backup (CRT-D)
Number of subjects: 1281
Study 26124205 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator only (ICD)
Number of subjects: 1281
Study 22612365 — intervention group
Group type: EXPERIMENTAL
Intervention: periosteum with alloplastic graft material
Number of subjects: 20
Study 22612365 — intervention group
Group type: COMPARATOR
Intervention: periosteum alone
Number of subjects: 20
Study 21186071 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of urinary Gb3 using electrospray ionization tandem mass spectrometry
Number of subjects: 28
Study 18316562 — intervention group
Group type: EXPERIMENTAL
Intervention: PC + bevacizumab (BPC arm)
Number of subjects: 878
Study 18316562 — intervention group
Group type: COMPARATOR
Intervention: PC arm
Number of subjects: 878
Study 16179584 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/d)
Number of subjects: 10
Study 16179584 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (200 mg.kg(‐1).d(‐1))
Number of subjects: 10
Study 16179584 — intervention group
Group type: COMPARATOR
Intervention: Aldosterone (250 nmol/L)
Number of subjects: 10
Study 16179584 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (2 micromol/L)
Number of subjects: 10
Study 11874386 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron (2 mg, single oral and intravenous doses)
Number of subjects: 48
Study 9892590 — intervention group
Group type: EXPERIMENTAL
Intervention: 192Ir
Number of subjects: 55
Study 9892590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 7770253 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial of labor
Number of subjects: 9
Study 7770253 — intervention group
Group type: COMPARATOR
Intervention: Elective cesarean
Number of subjects: 9
Study 2202512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime 2 gm intravenously every 12 hours with doxycycline 100 mg intravenously twice daily (Rx 1)
Number of subjects: 67
Study 2202512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin 2 gm intravenously every six hours with doxycycline 100 mg intravenously twice daily (Rx 2)
Number of subjects: 67
Study 2202512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime 2 gm intravenously every eight hours with doxycycline 100 mg intravenously twice daily (Rx 3)
Number of subjects: 67
Study 2202512 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 900 mg intravenously every eight hours with a 2‐mg/kg loading dose of gentamicin followed by 1.5 mg/kg intravenously every eight hours (Rx 4)
Number of subjects: 67
Study 6813604 — intervention group
Group type: EXPERIMENTAL
Intervention: Family member reinforcement
Number of subjects: 402
Study 6813604 — intervention group
Group type: COMPARATOR
Intervention: Triage method for health education interventions
Number of subjects: 402
Study 31776695 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract
Number of subjects: 0
Study 31776695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31532808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 505
Study 31532808 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing work to come to the CHC
Number of subjects: 505
Study 31532808 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of depressive symptoms
Number of subjects: 505
Study 31532808 — intervention group
Group type: EXPERIMENTAL
Intervention: Told by someone important to come to the CHC
Number of subjects: 505
Study 31532808 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter distance to the treatment site
Number of subjects: 505
Study 28592069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application education and follow-up
Number of subjects: 132
Study 28592069 — intervention group
Group type: COMPARATOR
Intervention: Traditional education (face-to-face and telephone)
Number of subjects: 132
Study 26486166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin 10/20 mg (ES10/20)
Number of subjects: 358
Study 26486166 — intervention group
Group type: COMPARATOR
Intervention: Statin dose-doubling (to S40 or A20)
Number of subjects: 358
Study 26486166 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg (R10)
Number of subjects: 358
Study 23628600 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 10mg
Number of subjects: 1347
Study 23628600 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 20mg
Number of subjects: 1347
Study 23628600 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5mg
Number of subjects: 1347
Study 23628600 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500mg
Number of subjects: 1347
Study 23628600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1347
Study 21554401 — intervention group
Group type: EXPERIMENTAL
Intervention: DFX-40 (deferasirox 40 mg/kg/d for 6 months)
Number of subjects: 38
Study 21554401 — intervention group
Group type: COMPARATOR
Intervention: DFX-20 (deferasirox 20 mg/kg/d for 6 months)
Number of subjects: 38
Study 21554401 — intervention group
Group type: COMPARATOR
Intervention: β-TM patients
Number of subjects: 38
Study 19842461 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity intervention (LIFE)
Number of subjects: 68
Study 19842461 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 17174223 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygosity for the 379V allele
Number of subjects: 123
Study 15095048 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral carotid endarterectomy (CE)
Number of subjects: 35
Study 15095048 — intervention group
Group type: COMPARATOR
Intervention: Surgically untreated uni-/bilateral carotid stenosis (CS)
Number of subjects: 35
Study 15095048 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 35
Study 12630983 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) 220 micro g
Number of subjects: 27
Study 12630983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 200 micro g
Number of subjects: 27
Study 12630983 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA) vs Mometasone furoate (MF)
Number of subjects: 27
Study 9427571 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 31
Study 9427571 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-SK)
Number of subjects: 31
Study 10150709 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients interpreting the term 'rare' in relation to death
Number of subjects: 0
Study 10150709 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients interpreting the term 'rare' in relation to severe heart attack
Number of subjects: 0
Study 10150709 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients interpreting the term 'rare' in relation to severe pneumonia
Number of subjects: 0
Study 3262857 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP vaccine
Number of subjects: 69
Study 3262857 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 69
Study 31332020 — intervention group
Group type: EXPERIMENTAL
Intervention: selinexor plus low-dose dexamethasone
Number of subjects: 0
Study 28712786 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) for 12 months
Number of subjects: 398
Study 25444717 — intervention group
Group type: EXPERIMENTAL
Intervention: FC2
Number of subjects: 300
Study 25444717 — intervention group
Group type: EXPERIMENTAL
Intervention: Woman's Condom
Number of subjects: 300
Study 25444717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupid
Number of subjects: 300
Study 25444717 — intervention group
Group type: EXPERIMENTAL
Intervention: VA w.o.w
Number of subjects: 300
Study 22545978 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-monitoring
Number of subjects: 161
Study 22545978 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of consistent self‐monitoring
Number of subjects: 161
Study 21633086 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued transfusions
Number of subjects: 79
Study 21633086 — intervention group
Group type: COMPARATOR
Intervention: Transfusion-halted group
Number of subjects: 79
Study 20088413 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuchal acupuncture and abdominal acupuncture
Number of subjects: 60
Study 20088413 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 60
Study 16245263 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (30 mg)
Number of subjects: 5
Study 16245263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 15329362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus F19 with penicillin
Number of subjects: 36
Study 15329362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus F19 with ciprofloxacin
Number of subjects: 36
Study 15329362 — intervention group
Group type: COMPARATOR
Intervention: Placebo with penicillin
Number of subjects: 36
Study 15329362 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ciprofloxacin
Number of subjects: 36
Study 15329362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus F19
Number of subjects: 36
Study 15329362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10649153 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Burch procedure
Number of subjects: 36
Study 10649153 — intervention group
Group type: COMPARATOR
Intervention: Suburethral sling
Number of subjects: 36
Study 9286225 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (5 g) with water (300 ml)
Number of subjects: 12
Study 9286225 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (5 g) with glucose drink (300 ml/330 kcal)
Number of subjects: 12
Study 9286225 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (5 g) with solid meal (530 kcal)
Number of subjects: 12
Study 8364350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg or 60 mg daily
Number of subjects: 214
Study 8364350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg daily
Number of subjects: 214
Study 8364350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (any dose)
Number of subjects: 214
Study 8364350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 3108527 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-514 5 mg
Number of subjects: 41
Study 3108527 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-514 20 mg
Number of subjects: 41
Study 3108527 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-514 40 mg
Number of subjects: 41
Study 3108527 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-514 (all doses)
Number of subjects: 41
Study 29189215 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral transperitoneal adrenalectomy (LTA)
Number of subjects: 83
Study 29189215 — intervention group
Group type: COMPARATOR
Intervention: Posterior retroperitoneoscopic adrenalectomy (PRA)
Number of subjects: 83
Study 28449303 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 214
Study 28449303 — intervention group
Group type: EXPERIMENTAL
Intervention: BI + group CBT
Number of subjects: 214
Study 28449303 — intervention group
Group type: EXPERIMENTAL
Intervention: BI + group PE
Number of subjects: 214
Study 28449303 — intervention group
Group type: COMPARATOR
Intervention: BI alone
Number of subjects: 214
Study 26596801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal implantation of sustained-release 5-fluorouracil 600 mg as local chemotherapy
Number of subjects: 202
Study 23332619 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 40 mg capsules orally once daily for 16 weeks
Number of subjects: 34
Study 23332619 — intervention group
Group type: COMPARATOR
Intervention: Placebo 40 mg capsules orally once daily for 16 weeks
Number of subjects: 34
Study 21172396 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 0
Study 21172396 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 0
Study 19825728 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor tendon transfer (group 1)
Number of subjects: 31
Study 19825728 — intervention group
Group type: COMPARATOR
Intervention: No adductor tendon transfer (group 2)
Number of subjects: 31
Study 21092029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion during aortic cross‐clamping (Group P)
Number of subjects: 30
Study 21092029 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (Group NP)
Number of subjects: 30
Study 16282544 — intervention group
Group type: EXPERIMENTAL
Intervention: CADASIL patients
Number of subjects: 14
Study 16282544 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched control subjects
Number of subjects: 14
Study 12192015 — intervention group
Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 220
Study 12192015 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 220
Study 9726738 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine/prednisone (n=19)
Number of subjects: 56
Study 9726738 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine/prednisone (n=11)
Number of subjects: 56
Study 9726738 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine/colchicine/prednisone (n=11)
Number of subjects: 56
Study 9726738 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone (n=15)
Number of subjects: 56
Study 9726738 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 56
Study 9726738 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 56
Study 7979607 — intervention group
Group type: EXPERIMENTAL
Intervention: PGG-glucan
Number of subjects: 34
Study 7979607 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 34
Study 2656042 — intervention group
Group type: EXPERIMENTAL
Intervention: MAb 96.5 followed by ZME-018
Number of subjects: 17
Study 2656042 — intervention group
Group type: EXPERIMENTAL
Intervention: MAb ZME-018 followed by 96.5
Number of subjects: 17
Study 2656042 — intervention group
Group type: COMPARATOR
Intervention: Each MAb followed by itself (controls)
Number of subjects: 17
Study 2656042 — intervention group
Group type: EXPERIMENTAL
Intervention: MAb 96.5 as first infusion
Number of subjects: 17
Study 2656042 — intervention group
Group type: EXPERIMENTAL
Intervention: MAb 96.5 as second infusion
Number of subjects: 17
Study 2656042 — intervention group
Group type: EXPERIMENTAL
Intervention: ZME-018 as first infusion
Number of subjects: 17
Study 2656042 — intervention group
Group type: EXPERIMENTAL
Intervention: ZME-018 as second infusion
Number of subjects: 17
Study 2656042 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity related to HAMA response
Number of subjects: 17
Study 1117249 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling procedures complemented by the appropriate rule statement
Number of subjects: 40
Study 1117249 — intervention group
Group type: COMPARATOR
Intervention: Modeling procedures alone
Number of subjects: 40
Study 31067356 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan with vincristine (VI) followed by multi-agent chemotherapy for 44 weeks
Number of subjects: 136
Study 31067356 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-agent chemotherapy including tirapazamine (TPZ) for 31 weeks
Number of subjects: 136
Study 31067356 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-agent chemotherapy without VI and TPZ for 31 weeks
Number of subjects: 136
Study 26565071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 557
Study 26565071 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin-A (CsA-ME)
Number of subjects: 557
Study 25175981 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 15
Study 25175981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 25175981 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 22665593 — intervention group
Group type: EXPERIMENTAL
Intervention: BioSand filter (BSF)
Number of subjects: 0
Study 22665593 — intervention group
Group type: COMPARATOR
Intervention: No BioSand filter (Control)
Number of subjects: 0
Study 18977267 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal conjugate vaccine (11PCV)
Number of subjects: 378
Study 17186261 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG 0.1% in glucose 5%
Number of subjects: 60
Study 17186261 — intervention group
Group type: COMPARATOR
Intervention: No ICG
Number of subjects: 60
Study 15133424 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 11723385 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 0
Study 11723385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9743162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (mean level=120 ppb)
Number of subjects: 15
Study 9743162 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 15
Study 9743162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure
Number of subjects: 15
Study 8061851 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 19
Study 8061851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3058238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and fluoxymesterone
Number of subjects: 63
Study 3058238 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen and danazol
Number of subjects: 63
Study 29746672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg q2w plus MTX
Number of subjects: 1197
Study 29746672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg q2w plus MTX
Number of subjects: 1197
Study 29746672 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 1197
Study 29746672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab (both dosages)
Number of subjects: 1197